These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32002175)

  • 21. Role of pirfenidone in the management of pulmonary fibrosis.
    Meyer KC; Decker CA
    Ther Clin Risk Manag; 2017; 13():427-437. PubMed ID: 28435277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.
    Nambiar AM; Anzueto AR; Peters JI
    PLoS One; 2017; 12(4):e0176312. PubMed ID: 28441449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study.
    Majewski S; Szewczyk K; Białas AJ; Miłkowska-Dymanowska J; Górski P; Piotrowski WJ
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity.
    Sverzellati N; Silva M; Seletti V; Galeone C; Palmucci S; Piciucchi S; Vancheri C; Poletti V; Tomassetti S; Karwoski R; Bartholmai BJ
    Eur Radiol; 2020 May; 30(5):2669-2679. PubMed ID: 32006172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Automated Computed Tomography analysis in the assessment of Idiopathic Pulmonary Fibrosis severity and progression.
    Romei C; Tavanti LM; Taliani A; De Liperi A; Karwoski R; Celi A; Palla A; Bartholmai BJ; Falaschi F
    Eur J Radiol; 2020 Mar; 124():108852. PubMed ID: 32028067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease.
    Khadawardi H; Mura M
    Respirology; 2017 Apr; 22(3):501-507. PubMed ID: 27862639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries.
    Pesonen I; Carlson L; Murgia N; Kaarteenaho R; Sköld CM; Myllärniemi M; Ferrara G
    Multidiscip Respir Med; 2018; 13():14. PubMed ID: 29785264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
    Higo H; Miyahara N; Taniguchi A; Senoo S; Itano J; Watanabe H; Oda N; Kayatani H; Ichikawa H; Shibayama T; Kajimoto K; Tanimoto Y; Kanehiro A; Maeda Y; Kiura K;
    Respir Investig; 2020 May; 58(3):185-189. PubMed ID: 32102769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Position Paper: Significance of the Forced Vital Capacity in Idiopathic Pulmonary Fibrosis].
    Behr J; Bonella F; Bonnet R; Gläser S; Grohé C; Günther A; Koschel D; Kreuter M; Kirsten D; Krögel C; Markart P; Müller-Quernheim J; Neurohr C; Pfeifer M; Prasse A; Schönfeld N; Schreiber J; Wirtz H; Witt C; Costabel U
    Pneumologie; 2015 Aug; 69(8):455-8. PubMed ID: 26227628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry.
    Fan Y; Bender SD; Conoscenti CS; Davidson-Ray L; Cowper PA; Palmer SM; de Andrade JA;
    Chest; 2020 Jun; 157(6):1522-1530. PubMed ID: 32004554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis.
    Doubková M; Švancara J; Svoboda M; Šterclová M; Bartoš V; Plačková M; Lacina L; Žurková M; Binková I; Bittenglová R; Lošťáková V; Merta Z; Šišková L; Tyl R; Lisá P; Šuldová H; Petřík F; Pšikalová J; Řihák V; Snížek T; Reiterer P; Homolka J; Musilová P; Lněnička J; Palúch P; Hrdina R; Králová R; Hortvíková H; Strenková J; Vašáková M
    Clin Respir J; 2018 Apr; 12(4):1526-1535. PubMed ID: 28862397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of forced expiratory volume in 1 second/forced vital capacity in idiopathic pulmonary fibrosis.
    Nishiyama O; Yamazaki R; Sano A; Yamagata T; Sano H; Iwanaga T; Higashimoto Y; Kume H; Tohda Y
    Chron Respir Dis; 2016 Feb; 13(1):40-7. PubMed ID: 26374300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment.
    Balestro E; Cocconcelli E; Giraudo C; Polverosi R; Biondini D; Lacedonia D; Bazzan E; Mazzai L; Rizzon G; Lococo S; Turato G; Tinè M; Cosio MG; Saetta M; Spagnolo P
    J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31540181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year.
    Collins BF; Spiekerman CF; Shaw MA; Ho LA; Hayes J; Spada CA; Stamato CM; Raghu G
    Chest; 2017 Jul; 152(1):103-112. PubMed ID: 28300570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial automated quantitative CT analysis in idiopathic pulmonary fibrosis: functional correlations and comparison with changes in visual CT scores.
    Jacob J; Bartholmai BJ; Rajagopalan S; Kokosi M; Egashira R; Brun AL; Nair A; Walsh SLF; Karwoski R; Wells AU
    Eur Radiol; 2018 Mar; 28(3):1318-1327. PubMed ID: 28963678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
    Vancheri C; Sebastiani A; Tomassetti S; Pesci A; Rogliani P; Tavanti L; Luppi F; Harari S; Rottoli P; Ghirardini A; Kirchgaessler KU; Albera C
    Respir Med; 2019 Sep; 156():78-84. PubMed ID: 31445389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.